Synthesis, pharmacology and preclinical evaluation of 11C-labeled 1,3-dihydro-2H-benzo[d]imidazole-2-ones for imaging γ8-dependent transmembrane AMPA receptor regulatory protein
作者:Zhen Chen、Wakana Mori、Xiaofei Zhang、Tomoteru Yamasaki、Patrick J. Dunn、Genwei Zhang、Hualong Fu、Tuo Shao、Yiding Zhang、Akiko Hatori、Longle Ma、Masayuki Fujinaga、Lin Xie、Xiaoyun Deng、Hua Li、Qingzhen Yu、Jian Rong、Lee Josephson、Jun-An Ma、Yihan Shao、Susumu Tomita、Ming-Rong Zhang、Steven H. Liang
DOI:10.1016/j.ejmech.2018.08.019
日期:2018.9
living brain and advance the translational development of AMPAR antagonists. Herein we report the design, synthesis and preclinical evaluation of a series of TARP γ-8 antagonists, amenable for radiolabeling, for the development of subtype-selective AMPAR PET imaging agents. Based on the pharmacology evaluation, molecular docking studies and physiochemical properties, we have identified several promising
α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体与诸如癫痫和精神分裂症的神经疾病的病理学有关。由于针对该靶标的泛拮抗剂通常在高剂量时会产生不良作用,因此,最近的药物开发方法之一已转变为亚型选择性AMPA受体(AMPAR)拮抗剂,特别是通过调节跨膜AMPAR调节蛋白(TARPs)。通过正电子发射断层扫描(PET)对AMPAR进行定量分析将有助于获得对活体大脑疾病状况的见解,并促进AMPAR拮抗剂的翻译发展。本文中,我们报道了一系列适于放射性标记的TARPγ-8拮抗剂的设计,合成和临床前评价,用于开发亚型选择性AMPAR PET显像剂。基于药理学评估,分子对接研究和理化特性,我们已经确定了几种用于体内PET研究的有前途的先导化合物3、17-19和21。所有候选化合物都以[11C] COCl2标记,具有较高的放射化学收率(13-31%RCY)和较高的摩尔活度(35-196 GBq /μmol)。示踪剂30([11C]